Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome

Table 4 Survival outcomes in association with telomerase expression stratified by adjuvant treatment

Variable	Overall survival		Disease-free survival
	HR (95% CI)*	AHR (95% CI)**	HR (95% CI)*	AHR (95% CI)**
Chemotherapy only (n = 119)
Low telomerase	1.00	1.00	1.00	1.00
High telomerase	2.05 (0.94 to 4.46)	3.15 (1.34 to 7.40)	1.32 (0.69 to 2.51)	2.04 (0.96 to 4.30)
Endocrine therapy only (n = 77)
Low telomerase	1.00	1.00	1.00	1.00
High telomerase	0.65 (0.19 to 2.23)	0.43 (0.11 to 1.66)	0.92 (0.28 to 3.03)	0.78 (0.22 to 2.69)
Chemo and endocrine therapy (n = 107)
Low telomerase	1.00	1.00	1.00	1.00
High telomerase	0.99 (0.37 to 2.63)	0.91 (0.33 to 2.55)	1.08 (0.52 to 2.23)	0.98 (0.46 to 2.09)

*HR, hazard ratio; 95% CI, 95% confidence interval.
** AHR, adjusted hazard ratio; adjusted for patient age at surgery, disease stage, tumor grade, histological type, estrogen- and progesterone-receptor status.

ISSN: 1465-542X